227 related articles for article (PubMed ID: 34216470)
1. High Prevalence of Plasmodium falciparum K13 Mutations in Rwanda Is Associated With Slow Parasite Clearance After Treatment With Artemether-Lumefantrine.
Straimer J; Gandhi P; Renner KC; Schmitt EK
J Infect Dis; 2022 Apr; 225(8):1411-1414. PubMed ID: 34216470
[TBL] [Abstract][Full Text] [Related]
2. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study.
Uwimana A; Umulisa N; Venkatesan M; Svigel SS; Zhou Z; Munyaneza T; Habimana RM; Rucogoza A; Moriarty LF; Sandford R; Piercefield E; Goldman I; Ezema B; Talundzic E; Pacheco MA; Escalante AA; Ngamije D; Mangala JN; Kabera M; Munguti K; Murindahabi M; Brieger W; Musanabaganwa C; Mutesa L; Udhayakumar V; Mbituyumuremyi A; Halsey ES; Lucchi NW
Lancet Infect Dis; 2021 Aug; 21(8):1120-1128. PubMed ID: 33864801
[TBL] [Abstract][Full Text] [Related]
3. Day 3 parasitemia and Plasmodium falciparum Kelch 13 mutations among uncomplicated malaria patients treated with artemether-lumefantrine in Adjumani district, Uganda.
Angwe MK; Mwebaza N; Nsobya SL; Vudriko P; Dralabu S; Omali D; Tumwebaze MA; Ocan M
PLoS One; 2024; 19(6):e0305064. PubMed ID: 38837973
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of arps10, fd, pfmdr-2, pfcrt and pfkelch13 gene mutations in Plasmodium falciparum parasite population in Uganda.
Ocan M; Ashaba FK; Mwesigwa S; Edgar K; Kamya MR; Nsobya SL
PLoS One; 2022; 17(5):e0268095. PubMed ID: 35511795
[TBL] [Abstract][Full Text] [Related]
5. Trends of Plasmodium falciparum molecular markers associated with resistance to artemisinins and reduced susceptibility to lumefantrine in Mainland Tanzania from 2016 to 2021.
Bakari C; Mandara CI; Madebe RA; Seth MD; Ngasala B; Kamugisha E; Ahmed M; Francis F; Bushukatale S; Chiduo M; Makene T; Kabanywanyi AM; Mahende MK; Kavishe RA; Muro F; Mkude S; Mandike R; Molteni F; Chacky F; Bishanga DR; Njau RJA; Warsame M; Kabula B; Nyinondi SS; Lucchi NW; Talundzic E; Venkatesan M; Moriarty LF; Serbantez N; Kitojo C; Reaves EJ; Halsey ES; Mohamed A; Udhayakumar V; Ishengoma DS
Malar J; 2024 Mar; 23(1):71. PubMed ID: 38461239
[TBL] [Abstract][Full Text] [Related]
6. Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa.
Ndayisaba G; Yeka A; Asante KP; Grobusch MP; Karita E; Mugerwa H; Asiimwe S; Oduro A; Fofana B; Doumbia S; Jain JP; Barsainya S; Kullak-Ublick GA; Su G; Schmitt EK; Csermak K; Gandhi P; Hughes D
Malar J; 2021 Dec; 20(1):478. PubMed ID: 34930267
[TBL] [Abstract][Full Text] [Related]
7. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda.
Uwimana A; Legrand E; Stokes BH; Ndikumana JM; Warsame M; Umulisa N; Ngamije D; Munyaneza T; Mazarati JB; Munguti K; Campagne P; Criscuolo A; Ariey F; Murindahabi M; Ringwald P; Fidock DA; Mbituyumuremyi A; Menard D
Nat Med; 2020 Oct; 26(10):1602-1608. PubMed ID: 32747827
[TBL] [Abstract][Full Text] [Related]
8. Novel Plasmodium falciparum k13 gene polymorphisms from Kisii County, Kenya during an era of artemisinin-based combination therapy deployment.
Maniga JN; Samuel M; John O; Rael M; Muchiri JN; Bwogo P; Martin O; Sankarapandian V; Wilberforce M; Albert O; Onkoba SK; Adebayo IA; Adeyemo RO; Akinola SA
Malar J; 2023 Mar; 22(1):87. PubMed ID: 36894982
[TBL] [Abstract][Full Text] [Related]
9. Modeling policy interventions for slowing the spread of artemisinin-resistant pfkelch R561H mutations in Rwanda.
Zupko RJ; Nguyen TD; Ngabonziza JCS; Kabera M; Li H; Tran TN; Tran KT; Uwimana A; Boni MF
Nat Med; 2023 Nov; 29(11):2775-2784. PubMed ID: 37735560
[TBL] [Abstract][Full Text] [Related]
10. Treatment Failure in a UK Malaria Patient Harboring Genetically Variant Plasmodium falciparum From Uganda With Reduced In Vitro Susceptibility to Artemisinin and Lumefantrine.
van Schalkwyk DA; Pratt S; Nolder D; Stewart LB; Liddy H; Muwanguzi-Karugaba J; Beshir KB; Britten D; Victory E; Rogers C; Millard J; Brown M; Nabarro LE; Taylor A; Young BC; Chiodini PL; Sutherland CJ
Clin Infect Dis; 2024 Feb; 78(2):445-452. PubMed ID: 38019958
[TBL] [Abstract][Full Text] [Related]
11. Escalating
van Loon W; Schallenberg E; Igiraneza C; Habarugira F; Mbarushimana D; Nshimiyimana F; Ngarambe C; Ntihumbya JB; Ndoli JM; Mockenhaupt FP
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0129923. PubMed ID: 38092677
[TBL] [Abstract][Full Text] [Related]
12.
Stokes BH; Dhingra SK; Rubiano K; Mok S; Straimer J; Gnädig NF; Deni I; Schindler KA; Bath JR; Ward KE; Striepen J; Yeo T; Ross LS; Legrand E; Ariey F; Cunningham CH; Souleymane IM; Gansané A; Nzoumbou-Boko R; Ndayikunda C; Kabanywanyi AM; Uwimana A; Smith SJ; Kolley O; Ndounga M; Warsame M; Leang R; Nosten F; Anderson TJ; Rosenthal PJ; Ménard D; Fidock DA
Elife; 2021 Jul; 10():. PubMed ID: 34279219
[TBL] [Abstract][Full Text] [Related]
13. Plasmodium falciparum K13 expression associated with parasite clearance during artemisinin-based combination therapy.
Silva M; Ferreira PE; Otienoburu SD; Calçada C; Ngasala B; Björkman A; Mårtensson A; Gil JP; Veiga MI
J Antimicrob Chemother; 2019 Jul; 74(7):1890-1893. PubMed ID: 30869127
[TBL] [Abstract][Full Text] [Related]
14. Increase in Kelch 13 Polymorphisms in Plasmodium falciparum, Southern Rwanda.
Bergmann C; van Loon W; Habarugira F; Tacoli C; Jäger JC; Savelsberg D; Nshimiyimana F; Rwamugema E; Mbarushimana D; Ndoli J; Sendegeya A; Bayingana C; Mockenhaupt FP
Emerg Infect Dis; 2021 Jan; 27(1):294-296. PubMed ID: 33350925
[TBL] [Abstract][Full Text] [Related]
15. Expansion of artemisinin partial resistance mutations and lack of histidine rich protein-2 and -3 deletions in Plasmodium falciparum infections from Rukara, Rwanda.
Schreidah C; Giesbrecht D; Gashema P; Young NW; Munyaneza T; Muvunyi CM; Thwai K; Mazarati JB; Bailey JA; Juliano JJ; Karema C
Malar J; 2024 May; 23(1):150. PubMed ID: 38755607
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of 3 and 5 day courses of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in an area of emerging artemisinin resistance in Myanmar.
Tun KM; Jeeyapant A; Myint AH; Kyaw ZT; Dhorda M; Mukaka M; Cheah PY; Imwong M; Hlaing T; Kyaw TH; Ashley EA; Dondorp A; White NJ; Day NPJ; Smithuis F
Malar J; 2018 Jul; 17(1):258. PubMed ID: 29996844
[TBL] [Abstract][Full Text] [Related]
17. K13 mutations and pfmdr1 copy number variation in Plasmodium falciparum malaria in Myanmar.
Win AA; Imwong M; Kyaw MP; Woodrow CJ; Chotivanich K; Hanboonkunupakarn B; Pukrittayakamee S
Malar J; 2016 Feb; 15():110. PubMed ID: 26911145
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of mutations in the cysteine desulfurase IscS (Pfnfs1) gene in recurrent Plasmodium falciparum infections following artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) treatment in Matayos, Western Kenya.
Gachie B; Thiong'o K; Muriithi B; Chepngetich J; Onchieku N; Gathirwa J; Mwitari P; Magoma G; Kiboi D; Kimani F
Malar J; 2023 May; 22(1):158. PubMed ID: 37202779
[TBL] [Abstract][Full Text] [Related]
19. Absence of association between polymorphisms in the K13 gene and the presence of Plasmodium falciparum parasites at day 3 after treatment with artemisinin derivatives in Senegal.
Madamet M; Kounta MB; Wade KA; Lo G; Diawara S; Fall M; Bercion R; Nakoulima A; Fall KB; Benoit N; Gueye MW; Fall B; Diatta B; Pradines B
Int J Antimicrob Agents; 2017 Jun; 49(6):754-756. PubMed ID: 28450175
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Confirmation of Artemisinin Resistance in Plasmodium falciparum from Patient Isolates, Southern Rwanda, 2019.
van Loon W; Oliveira R; Bergmann C; Habarugira F; Ndoli J; Sendegeya A; Bayingana C; Mockenhaupt FP
Emerg Infect Dis; 2022 Apr; 28(4):852-855. PubMed ID: 35318931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
